Kura Oncology
(NASDAQ) KURA
Kura Oncology Financials at a Glance
Market Cap
$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$71.64M
Net Income (TTM)
-$294.57M
EPS (TTM)
-$3.35
P/E Ratio
-3.58
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Price
$11.99
Volume
2,804
Open
$11.22
Price
$11.99
Volume
2,804
Open
$11.22
Previous Close
$11.99
Daily Range
$11.03 - $12.00
52-Week Range
$5.45 - $12.49
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.09 (Average)
Price
$11.99
Volume
2,804
Open
$11.22
Previous Close
$11.99
Daily Range
$11.03 - $12.00
52-Week Range
$5.45 - $12.49
Estimated Earnings Date
Aug 6, 2026
KURA News
KURA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Kura Oncology
Industry
Biotechnology
Sector
Health CareEmployees
260
CEO
Troy E. Wilson, PhD
Website
www.kuraoncology.comHeadquarters
San Diego, CA 92121, US
KURA Financials
Key Financial Metrics (TTM)
Gross Margin
94.66%
Operating Margin
-443.54%
Net Income Margin
-411.19%
Return on Equity
-141.95%
Return on Capital
-156.03%
Return on Assets
-45.14%
Earnings Yield
-27.93%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
88.77M
Volume
2.80K
Avg. Volume
1.75M
Financials (TTM)
Gross Profit
$67.81M
Operating Income
-$317.75M
EBITDA
-$292.27M
Operating Cash Flow
-$77.99M
Capital Expenditure
-$6.47M
Free Cash Flow
-$84.46M
Cash & ST Invst.
$580.82M
Total Debt
$24.27M
Kura Oncology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$18.27M
+29.5%
Gross Profit
$17.65M
+25.1%
Gross Margin
96.62%
N/A
Market Cap
$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.09M
N/A
Employees
260
N/A
Net Income
-$73.33M
-27.7%
EBITDA
-$72.63M
-26.7%
Quarterly Fundamentals
Total Cash
$580.82M
-11.8%
Total Debt
$24.27M
+25.4%
Accounts Receivable
$13.65M
-72.0%
Inventory
$843.00K
N/A
Long Term Debt
$22.99M
+48.1%
Short Term Debt
$1.28M
-66.5%
Return on Assets
-45.14%
N/A
Return on Invested Capital
-57.66%
N/A
Free Cash Flow
-$85.98M
-19.1%
Operating Cash Flow
-$85.85M
-19.4%